脂肪、肌肉与抗肥胖药物在心血管疾病预防中的作用
本文综述了GLP-1受体激动剂等抗肥胖药物治疗中肌肉流失的问题及其机制,探讨了肌生成抑制素/激活素通路抑制剂等新兴药物保留瘦体重的潜力,并强调抗阻训练和优化蛋白质摄入等策略。文章呼吁肥胖治疗应从单纯减重转向高质量减重,即保留或增加肌肉质量,以优化体成分并支持持久的心血管风险降低。
要点
- GLP-1受体激动剂减重伴随瘦体重包括骨骼肌的丢失,可能削弱长期心血管获益。
- 抗阻训练是目前推荐的药物减重期间保留骨骼肌和功能能力的策略。
- 肥胖治疗范式需转向高质量减重,将保留瘦体重作为治疗目标和试验终点。
核心结论
- 肥胖治疗需从总体重减少转向高质量减重,即保留或增强肌肉质量,以优化体成分并支持持久的心血管风险降低。
研究设计与样本
- 本文为综述,回顾了药物治疗减重中肌肉流失的证据、机制、新兴保留瘦组织的药物及优化体成分的策略。
主要发现
- GLP-1受体激动剂减重一致性地包括脂肪量和瘦体重(包括骨骼肌)的减少。
- 肌肉流失是多因素的,与热量限制、合成抵抗和激素变化有关。
- 靶向肌生成抑制素/激活素通路的药物、配体陷阱和选择性雄激素受体调节剂可能增加肌肉质量并与肠促胰素治疗有协同获益。
- 抗阻训练是目前药物减重期间保留骨骼肌和功能能力的建议策略。
- 优化蛋白质摄入和营养补充剂等辅助策略可能进一步减轻肌肉分解代谢。
临床怎么用
- 在GLP-1受体激动剂等药物减重过程中,应关注瘦体重和骨骼肌丢失,评估肌少症和衰弱风险。
- 推荐抗阻训练以保留骨骼肌和功能能力,并可考虑优化蛋白质摄入等辅助策略。
- 未来研究应以瘦体重保留为治疗目标,重新定义试验终点,并验证新兴联合干预以优化体成分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapid expansion of anti-obesity treatments with glucagon-like peptide-1 receptor agonists has redefined weight management. A consistent component of this weight loss, however, involves not only fat mass but also lean body mass, including skeletal muscle. This raises concerns regarding sarcopenia, frailty, and metabolic resilience that may attenuate long-term cardiovascular risk reduction. Muscle loss with these drugs is multifactorial, related to caloric restriction, anabolic resistance, and hormonal shifts. Emerging agents targeting the myostatin/activin pathway, ligand traps, and selective androgen receptor modulators may increase muscle quality and have synergistic benefit with incretin-based therapies. Resistance training is currently the suggested strategy for preserving skeletal muscle and functional capacity during pharmacologic weight loss, while adjunctive strategies such as optimized protein intake and nutraceuticals may further mitigate muscle catabolism. A paradigm shift is needed in obesity treatment away from total weight loss towards high-quality weight loss that preserves or enhances muscle mass, optimizing body composition and supporting durable cardiovascular risk reduction. Future research should study lean mass preservation as a treatment goal, redefine trial endpoints, and validate emerging combination interventions for optimal body composition. This manuscript reviews the evidence on muscle loss with pharmacologic weight loss therapies, its mechanistic underpinnings, explores emerging agents designed to preserve lean tissue, and outlines strategies to optimize body composition in the context of cardiovascular prevention.
引用
- Khan MS, Dawood MH, Handelsman Y, et al. Fat, muscle, and anti-obesity medications in cardiovascular disease prevention. Eur Heart J. 2026. PMID: 41914150. doi:10.1093/eurheartj/ehag201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。